1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 4
1.2 List of Figures 4
2 Introduction 6
2.1 What Is This Report About? 6
2.2 Diabetes Care Devices Market Segmentation 6
2.3 Definitions of Markets Covered in the Report 7
3 Diabetes Care Devices Market, India 9
3.1 Diabetes Care Devices Market, India, Revenue ($m), 2015-2025 9
3.2 Diabetes Care Devices Market, India, Revenue Mix ($m), 2019 11
3.3 Diabetes Care Devices Market, India, Category Contribution by Revenue ($m), 2019 12
3.4 Diabetes Care Devices Market, India, Revenue ($m), 2015-2025 13
3.5 Diabetes Care Devices Market, India, Volume (Units), 2015-2025 15
3.6 Diabetes Care Devices Market, India, Volume (Units), 2015-2025 17
3.7 Diabetes Care Devices Market, India, Company Share by Revenue ($m), 2019 19
4 Glucose Monitoring Market, India 21
4.1 Glucose Monitoring Market, India, Revenue ($m), 2015-2025 21
4.1.1 Blood Glucose Meters Market, India, Revenue ($m), by Segment, 2015-2025 23
4.2 Glucose Monitoring Market, India, Volume (Units), 2015-2025 25
4.2.1 Blood Glucose Meters Market, India, Volume (Units), by Segment, 2015-2025 27
4.3 Glucose Monitoring Market, India, Average Price ($), 2015-2025 29
4.4 Glucose Monitoring Market, India, Distribution Share by Revenue ($m), 2019 30
4.5 Glucose Monitoring Market, India, Company Share by Revenue ($m), 2019 31
5 Insulin Delivery Market, India 32
5.1 Insulin Delivery Market, India, Revenue Mix ($m), 2019 32
5.2 Insulin Delivery Market, India, Segment Contribution (%), 2019 33
5.3 Insulin Delivery Market, India, Revenue ($m), 2015-2025 34
5.3.1 Insulin Pens Market, India, Revenue ($m), by Segment, 2015-2025 36
5.3.2 Insulin Pumps Market, India, Revenue ($m), by Segment, 2015-2025 38
5.4 Insulin Delivery Market, India, Volume (Units), 2015-2025 40
5.4.1 Insulin Pens Market, India, Volume (Units), by Segment, 2015-2025 42
5.4.2 Insulin Pumps Market, India, Volume (Units), by Segment, 2015-2025 44
5.5 Insulin Delivery Market, India, Average Price ($), 2015-2025 46
5.6 Insulin Delivery Market, India, Distribution Share by Revenue ($m), 2019 47
5.7 Insulin Delivery Market, India, Company Share by Revenue ($m), 2019 48
6 Overview of Key Companies in India, Diabetes Care Devices Market 50
6.1 DexCom Inc 50
6.1.1 Company Overview 50
6.2 Novo Nordisk AS 50
6.2.1 Company Overview 50
6.3 Medtronic Plc 50
6.3.1 Company Overview 50
6.4 Abbott Laboratories 51
6.4.1 Company Overview 51
6.5 Sanofi 51
6.5.1 Company Overview 51
6.6 Eli Lilly and Co 51
6.6.1 Company Overview 51
6.7 F. Hoffmann-La Roche Ltd 52
6.7.1 Company Overview 52
6.8 Insulet Corp 52
6.8.1 Company Overview 52
7 Diabetes Care Devices Market Pipeline Products 53
8 Financial Deals Landscape 54
8.1 Debt Offerings 54
8.1.1 Piramal Enterprises Raises USD99.5 Milion in Private Placement of
10.25% Debentures Due 2021 54
8.1.2 Piramal Enterprises to Raise up to USD247 Million in Private Placement of Convertible Debentures 55
8.2 Equity Offerings 57
8.2.1 Piramal Enterprises Raises USD515.7 Million in Rights Offering of Shares 57
9 Recent Developments 59
9.1 Corporate Communications 59
9.1.1 Dec 03, 2019: Siddharth Mittal takes over as CEO and Joint Managing Director of Biocon 59
9.2 Financial Announcements 59
9.2.1 Feb 04, 2020: Piramal Enterprises announces consolidated results for Q3 & 9M FY2020 ended December 31, 2019 59
9.2.2 Oct 23, 2019: Biocon Q2FY20 earnings revenue at Rs 1,611 Cr, Up 17 %; EBITDA at Rs 441 Cr, Up 12%; Net Profit (excluding exceptional item) at Rs 189 Cr, Up 3% 61
9.2.3 Oct 21, 2019: Piramal Enterprises announces consolidated results for the second quarter & half year ended September 30, 2019 65
9.2.4 Oct 16, 2019: Abbott reports third-quarter 2019 results 65
9.2.5 Jul 30, 2019: Piramal Enterprises announces consolidated results for the quarter ended June 30, 2019 68
9.2.6 Jul 25, 2019: Biocon Q1FY 20 revenue rs 1,490Cr, up 25%; EBITDA up 51% at rs 462Cr 68
9.2.7 Apr 25, 2019: Biocon Q4FY19 Revenue Rs 1,557 Cr, Up 26%; EBITDA Up 43% at Rs 431 Cr; Net Profit Up 64% at Rs 214 Cr 71
9.3 Legal And Regulatory 73
9.3.1 Feb 27, 2020: Biocon's small molecules API manufacturing facility completes post – approval and GMP U.S. FDA inspection 73
9.3.2 Feb 22, 2020: Biocon's insulin manufacturing facility in Malaysia completes U.S. FDA (PAI) inspection 74
9.3.3 Jan 20, 2020: Biocon's oral solid dosage manufacturing facility completes pre-approval U.S. FDA inspection with zero observations 74
9.3.4 Nov 05, 2019: Biocon’s Biologics Drug Products facility in Bengaluru receives EIR from U.S. FDA 74
9.3.5 Sep 20, 2019: U.S. FDA completes pre-approval inspection of two new Biocon Biologics facilities in Bengaluru 75
9.3.6 Jul 08, 2019: Pre -Approval U.S. FDA Inspection Conducted at Biocon's Insulins Facilities in Malaysia 75
9.3.7 Jul 08, 2019: Biocon provides update on FDA inspection of its insulin facilities in Malaysia 75
9.3.8 Jun 14, 2019: Biocon Biologics facilities In Bengaluru receive EU GMP Certification 76
9.4 Other Significant Developments 76
9.4.1 Dec 12, 2019: HemoCue, the pioneer and global leader in Hemoglobin point-of-care testing to further strengthen National Activities in the Combat against Anemia in India 76
9.4.2 Nov 05, 2019: Thermo Fisher Scientific highlights expanded pharma services capabilities during CPhI 77
9.4.3 May 23, 2019: Ypsomed increases EBIT and invests in long-term profitability 78
10 Appendix 81
10.1 Research Methodology 82
10.1.1 Coverage 82
10.1.2 Secondary Research 82
10.1.3 Primary Research 83
10.1.4 Market Modeling and Forecasting 83
10.1.5 Company Share Analysis 85
10.1.6 Distribution Share Analysis 85
10.1.7 Benchmarking 86
10.2 GlobalData Consulting 86
10.3 Contact Us 87
10.4 Disclaimer 87